Latest news

• Hardy returns to Genentech as CEO

  In the US, the FDA has already approved three Herceptin copycats – Celltrion and Teva’s Herzuma, Samsung Bioepis’ Ontruzant and Myland’s Ogivri, however the companies will have to wait until ... It’s a slightly different story for the EU however

• Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz

  and MSD’s Ontruzant ($20m).

• Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more

  This follows hot on the heels of MSD (working with Samsung Bioepsis) that launched the first Herceptin biosimilar, Ontruzant, in March.

• MSD launches EU’s first biosimilar Herceptin in UK

  Ontruzant was approved by the EMA last November for the full range of registered indications for Herceptin, including early breast cancer, metastatic breast cancer and metastatic gastric cancer. ... Ontruzant was the fourth biosimilar developed by the

• Roche faces biosimilar blitz in 2018

  But Roche’s cancer antibody isn’t its only drug battling for market share - breast cancer blockbuster Herceptin (trastuzmab) also has a biosimilar rival in the form of Samsung Bioepis’ Ontruzant,